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Abstract
Background: Bacillus thuringiensis Cry toxins, that are used worldwide in insect control, kill insects by a mechanism that
depends on their ability to form oligomeric pores that insert into the insect-midgut cells. These toxins are being used
worldwide in transgenic plants or spray to control insect pests in agriculture. However, a major concern has been the
possible effects of these insecticidal proteins on non-target organisms mainly in ecosystems adjacent to agricultural fields.
Methodology/Principal Findings: We isolated and characterized 11 non-toxic mutants of Cry1Ab toxin affected in different
steps of the mechanism of action namely binding to receptors, oligomerization and pore-formation. These mutant toxins
were analyzed for their capacity to block wild type toxin activity, presenting a dominant negative phenotype. The dominant
negative phenotype was analyzed at two levels, in vivo by toxicity bioassays against susceptible Manduca sexta larvae and in
vitro by pore formation activity in black lipid bilayers. We demonstrate that some mutations located in helix a-4 completely
block the wild type toxin activity at sub-stoichiometric level confirming a dominant negative phenotype, thereby
functioning as potent antitoxins.
Conclusions/Significance: This is the first reported case of a Cry toxin dominant inhibitor. These data demonstrate that
oligomerization is a fundamental step in Cry toxin action and represent a potential mechanism to protect special
ecosystems from the possible effect of Cry toxins on non-target organisms.
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Introduction
Bacillus thuringiensis (Bt) bacteria produce crystal proteins
(denominated also Cry toxins) that have insecticidal activity.
One of the most successful applications of Cry proteins has been
their expression in transgenic crops resulting in their effective
protection from insect damage and lowering the use of chemical
insecticides [1]. Extensive studies show that Cry toxins used in
transgenic crops are safe to the environment and non-toxic to
other organisms [2–4]. Nevertheless, there are still concerns
related to the possible impact of by products from transgenic Bt
crops as Bt-cotton and Bt-corn on non-target organisms in
ecosystems adjacent to agricultural fields [5–9].
Pore-forming toxins are important virulent-factors in different
diseases induced by several mammalian-pathogenic bacteria [10].
Based on an understanding of their mechanism of action, different
strategies have been proposed to neutralize their action [11].
Among these strategies, the use of neutralizing antibodies that
recognize toxin regions involved in receptor binding or the use of
fragments of toxin-receptors were shown to efficiently protect the
cells from intoxication [12,13]. In addition, dominant negative
(DN) inhibitors which are inactive mutant-toxins, able to form
oligomer structures but affected in their pore formation activity,
work as powerful inhibitors since they are able to co-assemble into
hetero-oligomers together with the wild type toxin resulting in an
effective inactivation of pore formation and toxicity [14–16].
Cry toxins produced by Bt are pore-forming toxins [1]. Their
mechanism of action is complex and involves several steps. In the
case of Lepidopteran-active Cry1A proteins, the binding to a
primary receptor, the cadherin protein, induces the cleavage of an
amino-terminal helix a-1 leading to toxin oligomerization [17,18].
Then the Cry oligomer binds to a second receptor. Second
receptors such as aminopeptidase N or alkaline phosphatase are
anchored to the membrane by a glycosylphosphatidylinositol-
anchor, and are localized within lipid rafts [18,19]. The oligomeric
toxin inserts into the membrane forming ionic pores causing
osmotic lysis of midgut epithelial cells and insect death [1,18].
Although it has been recognized for decades that Cry toxins
exert their toxic effect by forming pores into the midgut cells of
their target insect, recently an alternative and opposing model was
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5545proposed. The alternative model proposed that after the
monomeric Cry toxin binds cadherin, a Mg
+2-dependent adenylyl
cyclase/PKA-signaling pathway is activated leading to cell death
[20]. In this alternative model, neither oligomerization or pore
formation are involved in Cry toxicity.
We hypothesized that mutants of Cry toxins affected in pore
formation might work as DN inhibitors. The Domain I of Cry
toxins is involved in pore formation [21–25]. In this work we
analyzed several mutations in helix a-4, in helix a-3 or in domain
II-loop 3. These mutants were affected in pore formation, toxin
oligomerization and receptor binding, respectively. We found that
DN phenotype is linked to mutations affected in pore formation
but that are still able to form oligomeric structures with the wild
type toxin resulting in a complete inhibition of its insecticidal
activity.
The fact that DN mutations blocked toxicity of wild type Cry
toxin, supports the concept that oligomerization is a fundamental
step in Cry toxin mode of action in agreement with the pore
formation model of Cry toxin action.
Results
Cry1Ab mutant characterization
We isolated and characterized Cry1Ab mutants affected at
different steps of their mode of action, namely receptor binding,
oligomerization and pore-formation to determine if any of them
showed a DN phenotype. First, we constructed a Cry1Ab mutant
G439D located in loop 3 of domain II. We selected this mutation
since a similar mutant, previously characterized in another Cry
toxin, the Cry1Ac [26], was shown to have reduced toxicity
toward M. sexta, reduced binding to BBMV and because the loop 3
region is important for binding with cadherin receptor [26–28].
Secondly, we used a previously described Cry1Ab mutant R99E,
located in helix a-3 that showed impaired toxin oligomerization
[21]. Finally, we constructed several point mutations in helix a-4
of Cry1Ab such as E129K, N135C, D136N, A140K, T142C,
T143D, and T143N, that in the context of Cry1Aa toxin showed
to be affected in pore formation and toxicity [22,23]. We also
constructed two double mutants, the D136N/T143D and
E129K/D136N. Binding analysis with P. xylostella BBMV, were
reported only for E129K and D136N mutants, revealing no effects
on binding of these two mutants, and suggesting that loss of
binding was not the reason for the loss of toxicity in these Cry1Aa
mutants [25]. However, the characterization of these mutants was
partial since the binding to M. sexta membranes, as well as the
oligomerization process was not analyzed.
All of the Cry1Ab mutants analyzed in this work produce
bipyramidal crystal inclusions similar to the wild type toxin with
exception of mutant T143N that was not further analyzed. With
the exception of two mutants, all other mutant toxins showed
severe reductions in toxicity when tested against M. sexta larvae
(Table 1). The two toxins that retain activity corresponds to
mutants D136N and A140K, located in helix a-4, that showed a
reduction of two- and four-fold in their insecticidal toxicity when
compared with the wild type toxin, respectively. The crystal
inclusions produced by Cry1Ab mutants were purified and
protoxins were activated with trypsin; all proteins produced a
similar 60 kDa activated toxin fragment, indicating no major
effects on toxin structure that would result in enhanced
susceptibility to protease action (data not shown).
To determine if the Cry1Ab mutants had altered receptor
binding, trypsin activated proteins were labeled with biotin and
their binding to M. sexta BBMV was analyzed (Fig. 1). All mutants
except G439D toxin, bound specifically to BBMV as shown in the
homologous binding competition assay. The exception was mutant
G439D that showed reduced binding to BBMV as was previously
reported in the context of Cry1Ac toxin [26]. Figure 1 shows that
the rest of biotinylated toxins bind to BBMV membranes isolated
from M. sexta larvae when assayed in the absence of competitor
(lanes marked 2). In contrast, in the presence of 500-fold molar
excess of unlabeled toxin competitor (lanes marked +) the binding
of biotinylated toxin is competed.
We then analyzed the ability of the mutant proteins to
oligomerize. In this assay the Cry1Ab mutant-protoxins were
proteolytically activated with M. sexta midgut proteases in the
presence SUV liposomes and the antibody scFv73 that mimics an
epitope of the cadherin receptor that interacts with loop 2 of
domain II [17,18,21]. The oligomeric structure was observed as a
low mobility 250-kDa band in a Western blot assay using a specific
anti-Cry1Ab antiserum. As shown in Figure 2, only mutant R99E,
located in helix a-3 was affected in oligomerization as previously
reported [21]. The oligomeric structure of wild type Cry1Ab toxin
was mainly found inserted into the membrane pellet, in contrast
with the helix a-4 mutants, that remained in the soluble fraction
Table 1. Toxicity of wild type and mutated Cry1Ab toxins







Wt Cry1Ab 1.3 (0.9–1.7)
R99E .2000 Helix a-3 of Domain I
E129K .2000 Helix a-4 of Domain I
N135C 16.4 (10.9–22.7) Helix a-4 of Domain I
D136N 2.8 (2.2–3.8) Helix a-4 of Domain I
A140K 5.3 (2.8–8.2) Helix a-4 of Domain I
T142C 34.9 (28.3–41.7) Helix a-4 of Domain I
T143D .2000 Helix a-4 of Domain I
D136N, T143D .2000 Helix a-4 of Domain I
E129K, D136N .2000 Helix a-4 of Domain I
G439D .2000 Loop 3 of Domain II
doi:10.1371/journal.pone.0005545.t001
Figure 1. Binding competition assays of Cry1Ab mutants to
BBMV of Manduca sexta larvae. Binding of biotin labeled toxins was
analyzed in the absence (lanes 2) or in the presence (lanes +) of 500-
fold molar excess of unlabeled toxin. The biotinylated toxins bound to
the vesicles, were visualized with streptavidin-HRP conjugate. The
Cry1Ab and all mutants located in domain I (helices a-3 or a-4) bound
specifically to BBMV only mutant G439D was affected in binding to the
M. sexta BBMV.
doi:10.1371/journal.pone.0005545.g001
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insertion (Fig. 2A). Finally, the G439D mutant, located in domain
II loop 3, also showed an oligomeric structure that was mainly
found inserted into the membrane.
Since our oligomeric assay utilizes the scFv73 antibody that
mimics the cadherin repeat 11 (CR11) region of the cadherin
receptor which recognizes loop 2 in domain II and considering
that the G439D mutation is located in a toxin region which
interacts with a different region of the cadherin receptor, i.e. the
CR12 fragment [28,29], we repeated the oligomerization assay of
G439D using a purified CR12 fragment from cadherin receptor,
instead of the scFv73 antibody. Under these conditions the
oligomerization of the G439D mutant was severely reduced when
compared with the wild type toxin (Fig 2B).
In vivo inhibition of toxin insecticidal activity
To compare the potency of the mutants as DN inhibitors, we
tested their ability to inhibit the toxicity of Cry1Ab to M. sexta
larvae. We fed the larvae with different mixtures of wild type and
mutant toxins. We used an equimolar ratio (1:1) as well as a lower
ratio (0.25:1 of mutant: wild type). Figure 3A shows that some
mutants located in helix a-4 completely blocked toxin action even
at sub-stoichiometric ratios. Mutants D136N and A140K did not
show DN phenotype because they were not severely affected in
toxicity (Table 1), showing an increase in mortality when mixed
with the wild type toxin at 1:1 ratio. The higher activity is due to
the fact that we used 2 ng/cm
2 of each toxin, one being wild type
Figure 2. Oligomerization of Cry1Ab proteins. Panel A, Cry1Ab and mutant protoxins were proteolytically activated with M sexta midgut
proteases in the presence of SUV liposomes and scFv73 antibody. Membrane pellets were recovered by centrifugation and the toxin detected by
Western blot using an anti-Cry1Ab antibody in the supernatant and in the membrane fraction. The oligomeric structure of 250-kDa of the Cry1Ab is
observed inserted into the membrane pellet, in contrast with the helix a-4 mutants, that remains in the soluble fraction. The mutant R99E, located in
helix a-3 did not form oligomeric structures. Panel B, Oligomerization of Cry1Ab and mutant G439D proteins performed as above but in the presence
of the cadherin CR12 fragment instead of scFv73 antibody. Under these conditions the oligomerization of the Cry1Ab wild type is observed inserted
into the membrane and oligomerization of G439D mutant was severely reduced. Panel C, Oligomerization of the mixtures of 1:1 Cry1Ab: Mutant
proteins performed as in Panel A. The oligomer of double mutants or in the 1:1 mixture of Cry1Ab with the double mutants is observed in the soluble
fraction.
doi:10.1371/journal.pone.0005545.g002
Figure 3. In vivo analysis of the Dominant Negative phenotype
of Cry1Ab mutants. Panel A, Toxicity assays against M sexta larvae
with Cry1Ab at 2 ng/cm
2 of diet (black bar) or with a mixture of the
same concentration of Cry1Ab wild type with the mutant proteins at
two different ratios, 0.25:1 mutant:wild type (white bars) or 1:1 (grey
bars). Some mutants of helix a-4 show a clear DN phenotype. Panel B,
Toxicity assays against Ms e x t alarvae as panel A but at 10:1
mutant:Cry1Ab ratio (dashed bars). R99E reduce toxicity of wild type
under this condition in contrast mutant G439D did not affect toxicity of
the wild type toxin.
doi:10.1371/journal.pone.0005545.g003
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showed reduced toxicity but remain active (Table 1). This mixture
represents, therefore, the additive mortality of the two toxin
proteins. In contrast, helix a-3 R99A and domain II-loop 3
G439D mutants did not show a DN phenotype. The R99A
mutant, showed a competition phenotype since only a high ratio of
10:1 reduced the toxicity of Cry1Ab. In contrast, the G439D
mutant showed no effect on Cry1Ab toxicity even at a 10:1 ratio
(Fig. 3B).
In vitro inhibition of toxin pore formation activity
To determine if pore formation inhibition by the DN mutants
depends on the ability to form hybrid complexes with wild type
toxin, we produced homo- and hetero-oligomers and measured
their ability to form conductive ion channels in black lipid bilayers.
Wild type Cry1Ab or the D136N/T143D and E129K/D136N
double mutants were activated in the presence of SUV liposomes
and scFv73 antibody as described above to produce oligomeric
structures. The hetero-oligomers were prepared by mixing the DN
mutants with the wild type in a 1:1 ratio during activation under
similar conditions described above. We analyzed oligomer
formation in the supernatant and pellet fractions, after centrifu-
gation of the activation reaction to separate toxin inserted into
liposomes from soluble proteins. Figure 2C shows that the 250-
kDa oligomer was observed mainly in the pellet in the case of
Cry1Ab. Nevertheless, in the case of the D136N/T143D and
E129K/D136N double mutants or in the 1:1 mixture of Cry1Ab
with the double mutants, the 250-kDa oligomers were observed in
the soluble fraction (Fig 2C). The soluble and membrane pellet
fractions of activation reactions were used to assay pore formation
activity in black lipid bilayer system as described previously [21].
The results indicated that oligomers produced by the mutant
toxins were severely affected in their pore formation activity when
compared with wild type toxin. The hetero-oligomers formed by a
mixture of wild type and mutant proteins were also inactive in
pore formation. Figure 4A shows representative traces of the
activity of Cry1Ab, the mutant E129K/D136N and the mixture of
these two proteins in lipid bilayers. Similar data were obtained
with the mutant D136N/T143D (data not shown). Current-
voltage curves are presented in figure 4B, showing that only wild
type Cry1Ab toxin has pore formation activity. These results are
consistent with the notion that DN mutants inactivate the wild
type toxic action in vivo by forming inactive hetero-oligomers
unable to insert into the membrane.
Discussion
The helix a-4 mutations analyzed in this study do not impair
toxin assembly in a pre-pore structure, but rather block an
essential conformational transition of the assembled complex
necessary for membrane insertion and pore formation. The helix
a-4 mutations that resulted in loss of toxin action act as DN anti-
toxins blocking toxicity and pore formation of wild type toxin.
These data strongly indicate that oligomerization and pore
formation are necessary steps in the mode if action of Cry toxins.
In contrast, the helix a-3 R99A mutant that is affected in the
process of oligomerization but retain binding capacities to
membrane receptors, displayed competitive binding for the
receptor at 10:1 ratio (mutant: wild type). Finally a mutant in
domain II, G439D, with altered binding interaction with the
BBMV and the cadherin receptor, did not compete with Cry1Ab
for binding and neither showed a DN phenotype.
These data are similar to some reported mutants of the anthrax
toxin; a mutant affected in its activation by furin, was unable to
undergo oligomerization, yet still bound to, and competed
receptor binding causing a competitive inhibition of toxin action
only at high at 10:1 ratios [30,31]. In another report an anthrax
mutant affected in toxin oligomerization did not show a DN
phenotype since it was unable to form hetero-oligomers with the
wild type toxin [32]. Finally, an anthrax mutant with altered
receptor binding did not compete for receptor binding and neither
affected wild type activity [32].
The molecular mechanism observed in DN phenotype involves
toxin oligomerization between different Cry toxin-monomers
forming hetero-oligomeric structures between mutant and wild
type monomers. The hetero-oligomer that is formed with the
double mutants and the wild type Cry1Ab toxin was severely
affected in membrane insertion and pore formation activity
suggesting a problem in the transition from pre-pore to pore as
was previously proposed for anthrax DN mutants [16].
Ifthe assembly ofthe Cry toxin oligomeric structureis an stochastic
procedure, then at a 1:1 ratio the probability to have at least one
subunit of the DN mutant in the resulting oligomeric-complex is high.
Figure 4. In vitro analysis of the Dominant Negative phenotype of E129K/D136N mutant. Pore formation activity of oligomeric structures
obtained as described in figure 2C. Panel A, Representative ionic channel records in lipid bilayers of most common transitions induced by oligomer
structures of Cry1Ab, E129K/D136N and a 1:1 mixture of Cry1Ab: E129K/D136N. The observed responses with wild type Cry1Ab showed stable
channels with high open probability. No ionic channels were observed either for the double mutant E129K/D136N or for the 1:1 mixture of Cry1Ab
with the double mutant. Records were obtained in 300:10 mM KCl (cis:trans), 10 mM CHES pH 9, at +60 mV. Panel B, Current/voltage (I/V)
relationship of macroscopic currents induced by oligomers of Cry1Ab ( ) and by oligomers produced from a 1:1 mixture of Cry1Ab and E129K/
D136N (n). The activity of the E129K/D136N mutant was also analyzed in the two fractions obtained after activation, the membrane pellet (#), and
supernatant fraction (&).
doi:10.1371/journal.pone.0005545.g004
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toxin activity, then at 1:1 ratio an effective blockage of toxin action is
expected. The fact that we found inhibition of wild type toxin activity
at 0.25:1 ratio strongly indicates that a single mutant subunit is
sufficient to inactivate the oligomer activity and that oligomerization
is an important step in toxin action.
The data presented here provides unequivocal evidence that
oligomerization is a key step in the mode of action of Cry1Ab and
further supports that pore formation is an important event
triggering insect cell death. These data support the pore-forming
model of the mode of action of Cry toxins and contradict the
model of cell death induced by the interaction with cadherin
receptor and subsequent induction of signal transduction pathway.
Recent reports raised the concern that the Cry1A toxins may
affect non-target organisms [5–9]. Nevertheless, Cry1A toxins
used in transgenic plants have been extensively shown to be
specific against target insects and safe to non-target organisms [2–
4]. In any case the antitoxins of Cry1A described here could be
used to inhibit toxicity of Cry toxins in special conditions like, for
example, for attenuation of an accidental effect or a release of
unregulated Cry toxin, since they offer an efficient alternative to
neutralize and counter the Bt toxin action that would help protect
potentially endangered organisms in a particular ecosystem.
Materials and Methods
Construction of Cry1Ab mutants
Mutants were produced by site-directed mutagenesis (Quick-
Change, Stratagene, La Jolla, CA) using the pHT315Ab harboring
cry1Ab gene. Appropriate oligonucleotides were synthesized for
each mutant. Automated DNA sequencing at UNAM’s facilities
verified the single point mutations. Acrystalliferous Bt strain 407
was transformed with recombinant plasmids and selected in Luria
broth at 30 uC supplemented with 10 mgm l
21 erythromycin. For
construction of double mutants we used pHT315Ab-D136N
harboring a point mutation D136N as template to introduce
additional point mutations as E129K or T143D.
Cry1Ab toxin purification
Bt transformant strains were grown at 30uC in nutrient broth
sporulation medium with erythromycin until complete sporula-
tion. Crystal inclusions were observed under phase contrast
microscopy and purified by sucrose gradients [33]. Crystals were
solubilized in 50 mM Na2CO3, 0.2% b-mercaptoethanol,
pH 10.5. The monomeric toxins were obtained by trypsin
activation in a mass ratio of 1:20 (1 h, 37uC). Phenylmethylsulfo-
nyl-fluoride (1 mM final concentration) was added to stop
proteolysis. The oligomeric Cry1Ab structure was produced as
described [17,21] by incubation with svFv73 antibody (1:4 toxin:
antibody ratio) purified as described [17] or with CR12 cadherin
fragment (1:1 ratio), purified as described [29,34] and 5% midgut
juice from M. sexta larvae, in 100 ml of solubilization buffer for 1 h
at 37uC in the presence of phosphatidylcholine-small unilamellar
vesicles (PC-SUV) at 12 mM final concentration. The membrane
fraction was separated by ultracentrifugation (30 min at
100,0006g) and the pellet was suspended in 20 mlo f1 0 m M
CHES, 150 mM KCl, pH 9.
Western Blot of Cry1Ab toxin
Cry1Ab and mutant proteins incorporated into PC-SUV or that
remained in the soluble fraction were boiled 5 min in Laemmli
sample loading buffer, separated in SDS-PAGE and electrotrans-
ferred onto nitrocellulose membrane. The proteins were detected in
Western blots as described [17,21] using polyclonal anti-Cry1Ab.
Bioassays against Manduca sexta larvae
Soluble protoxins (from 0.1 to 2000 ng/cm
2) were applied onto
the diet surface of 24-well plates as described [17]. Protein was
determined by the Bradford assay. Mortality was recorded after
seven days and lethal concentration (LC50) estimated by Probit
(Polo-PC LeOra Software). For DN assays different ratios of
mutant: wild type (0.25:1, 1:1 and 10:1; w: w) were assayed. The
concentration of wild type protoxin used in DN-bioassays was 2 ng
of toxin per cm
2 of diet.
Preparation of Brush Border Membrane Vesicles (BBMV)
M. sexta eggs were reared on artificial diet. BBMV from fourth
instar M. sexta larvae were prepared as reported [35].
Toxin binding assay
Binding assays were done with 10 mg BBMV protein and 5 nM
biotinylated Cry1Ab toxins as described [21]. We used 500-fold
excess of unlabeled toxins to compete binding. Unbound toxin was
washed by centrifugation and resulting membrane pellet was boiled
in Laemmli sample loading buffer, loaded onto SDS-PAGE,
transferred to nitrocellulose membranes and labeled-toxin bound
to the vesicles, was visualized by incubating with streptavidin-HRP
conjugate and developed with luminol as described [21].
Pore forming activity of Cry1Ab toxins
Black lipid bilayers were made as reported [36] with
Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) (Avanti Polar
Lipids). Buffers 300 mM KCl, 10 mM CHES, pH 9 and 10 mM
KCl, 10 mM CHES, pH 9 were added to the cis and trans
compartments, respectively. Once a bilayer was formed, the
membrane or soluble fractions containing the activated Cry1Ab
toxins (wild type, mutant or mixture of wild type with mutant)
were added to the cis compartment. Single-channel currents were
recorded with a Dagan 3900A patch-clamp amplifier (Dagan
Corp., Minneapolis, MN) as described [21]. Currents were filtered
at 200 or 500 Hz, digitalized on-line at 1 or 2 kHz, and analyzed
using a Digidata 1200 interface and Axotape and pClamp software
(Axon Instruments, Foster City, CA).
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